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Introduction: Thyroid hormone has profound effects on a number of metabolic processes 
in virtually all tissues but the cardiovascular manifestations are prominent usually creating 
a hyperdynamic circulatory state. Thyrotoxicosis is not a common cause of congestive heart 
failure among black communities.
Objectives: To determine the hospital prevalence, clinical characteristics and echocardiographic 
findings in patients with thyrotoxicosis who present with congestive heart failure (CCF) in the 
eastern part of Nigeria.
Subjects and methods: A total of 50 subjects aged 15 years and above who were diagnosed 
as thyrotoxic following clinical and thyroid function tests were consecutively recruited. Fifty 
age- and sex-matched controls with no clinical or biochemical evidence of thyrotoxicosis and 
no comorbidities were used as controls. Two-dimensional echocardiography was carried out on 
all the subjects. CCF was determined clinically and echocardiographically.
Results: Eight patients (5 females and 3 males) out of a total of 50 thyrotoxic patients presented 
with congestive heart failure.
Conclusion: The study revealed that congestive heart failure can occur in thyrotoxicosis in 
spite of the associated hyperdynamic condition. The underlying mechanism may include direct 
damage by autoimmune myocarditis, congestive circulation secondary to excess sodium, and 
fluid retention.
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Introduction
Thyroid hormone has profound effects on a number of metabolic processes in virtually 
all tissues with the cardiovascular manifestations most prominent. Thyrotoxicosis cre-
ates a hyperdynamic circulatory state because of a marked fall in peripheral vascular 
resistance and associated increase in venous return, increased total blood volume, 
increased cardiac contractility and heart rate. In spite of the increased cardiac con-
tractile state, congestive heart failure with reduced fractional shortening and ejection 
fraction still occurs in thyrotoxicosis.
Congestive heart failure in thyrotoxicosis may present with normal or reduced left 
ventricular systolic function and dilated heart. This may result from a combination of 
hypervolemic burden, tachyarrhythmias, congestive circulation secondary to excess 
sodium and fluid retention related to hyperthyroidism and secondary autoimmune 
myocarditis related to Graves’ disease.1
Thyrotoxicosis is a rare cause of heart failure and there are very few echocardio-
graphic reports on thyrotoxicosis presenting as congestive heart failure in Nigeria. 
Kolawole et al2 studied 50 cases of thyrotoxicosis in   Ile-ife, western Nigeria and Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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reported that 7 patients (14%) had congestive heart failure. 
Danbauchi et al3 in Zaria,   northern Nigeria reported 11 cases 
out of 122 thyrotoxicosis patients who had clinical symptoms 
and signs of heart failure. The authors are not aware of any 
echocardiographic study on individuals with thyrotoxicosis 
that has been done in the eastern part of Nigeria, comprising 
9 states out of the 36 states of Nigeria. This geographical 
location embraces about 40 million of the 150 million popu-
lation of Nigeria.
The purpose of this study was to determine the hospital 
prevalence, clinical characteristics and echocardiographic 
findings in patients with thyrotoxicosis who present with 
congestive heart failure in the eastern part of Nigeria.
Methods
We studied 50 patients who were aged 15 years or older, of 
both sexes and diagnosed of thyrotoxicosis in the medical out 
patients unit of the University of Nigeria Teaching Hospital 
(UNTH) Enugu, following clinical and thyroid function tests. 
Thyrotoxic patients were recruited consecutively as they pre-
sented in the medical outpatients unit over a one year period. 
Informed consent was obtained from all the subjects. The 
Ethical committee of UNTH approved the study.
Patients who were found to be in heart failure following 
clinical assessment which demonstrated congestive symp-
toms: breathlessness, paroxysmal nocturnal dyspnea, ortho-
pnea, coughing and leg swelling were identified and recruited 
into the study. Thyroid function tests were done with kits 
from Syntron Bioresearch Inc USA.4 The Syntron kits have 
the following intra-assay coefficient of variation: serum-free 
tri-iodothyronine (T3) – (6.8%), thyroid-stimulating hormone 
of (TSH) – (4.3%), total free tri-iodothyronine (T3) – (4.4%), 
total tetraiodothyronine (T4) – (7.2%).4 Comparison between 
Syntron kit and Abbot Kit showed a correlation coefficient 
of 0.09869.4 All the patients had electrocardiography and tran-
sthoracic echocardiography done with Sonos 2000 Hewlett 
Packard machine. Two-dimensional echocardiographic 
examinations were performed in all subjects with 3.5 MHz 
transducer according to the recommendations of the 
  American Society of Echocardiography.5
The following were excluded from the study: patients 
who had pre-existing hypertension, diabetes mellitus,   anemia, 
coronary artery disease, exposure to illicit drugs, herbal 
or any cardiotoxic agents. All pregnant women were also 
excluded from the study.
Fifty age- and sex-matched controls with no clinical or 
biochemical evidence of thyrotoxicosis and no comorbidities 
were included.
Definitions
The diagnosis of thyrotoxicosis was established in the pres-
ence of a serum free T3 . 4.2 pg/L and a concomitant sup-
pressed TSH of ,0.5 µU/mL.
Left ventricular systolic dysfunction was defined by 
any of the following: (i) left ventricular ejection fraction 
(LVEF) ,50%, (ii) fractional shortening (FS) ,18%, 
(iii) cardiac index ,2.8 L/min/m2, (iv) cardiac output 
,4 L/min, (v) mean velocity of circumferential fiber 
shortening ,1.02 circ/sec, and (vi) peak aortic systolic 
velocity ,72 cm/sec.
Dilated thyrotoxic heart muscle disease was defined as 
(i) end diastolic diameter .6.0 cm, (ii) end systolic diam-
eter .2.5 cm, (iii) LVEF , 50%, and (iv) FS , 18%.1,5
statistical analysis
Continuous variables were expressed as mean ± 1 standard 
error of mean (SEM). Statistical comparisons were per-
formed using Student’s t-test. Calculations were performed 
using SPSS software (SPSS Inc., Chicago, IL) P , 0.05 was 
considered significant.
Results
Demographic characteristics
All the patients were black and came from the eastern part 
of Nigeria. Eight patients – (16%) (consisting of 5 females 
and 3 males) out of a total number of 50 thyrotoxic patients 
presented with congestive heart failure. The patients were 
predominantly Igbos, with only one from Efik tribe in Akwa 
Ibom State. Their mean age compared with control was not 
significantly different. Their mean weight was 56 kg (± 4.1): 
range 52–72 kg. This is significantly lower than the weight 
65 kg (±5.7): range 64–78 kg of the controls (P , 0.05) 
(Table 1).
clinical characteristics and thyroid 
function test
The 8 patients who had congestive heart failure presented 
with symptoms of congestion, dyspnea, coughing and leg 
swelling, as well symptoms suggestive of thyrotoxicosis. 
These included palpitation, heat intolerance, tremulous-
ness, increased sweating. They all had Graves’ disease. The 
mean heart rate was significantly higher in the thyrotoxicosis 
patients than in the control (102 bpm vs 78 bpm, P , 0.01) 
whereas there were no significant differences in the mean 
systolic blood pressure and the mean diastolic blood pressure 
between the test group and control.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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The mean serum T3 was 5.9 (0.09) ng/mL and this was 
significantly higher than a mean of 2.3 (0.4) ng/mL in the 
control (P , 0.01). The mean serum TSH was significantly 
lower in the thyrotoxicosis patients than in the control 
(P , 0.01) (Table 1).
Echocardiographic findings
Echocardiography showed that 5 patients had ejection frac-
tion (LVEF) of ,50%.
Fractional shortening (FS) of ,18% was found in 
6 patients (12%), cardiac index of ,2.8 L/min/m2 in 
5 patients, cardiac output of ,5 L in 5 patients (10%), veloc-
ity of circumferential fiber shortening of ,1.02 circ/sec in 
5 patients (10%), aortic maximum velocity of ,72 cm/sec in 
5 patients (10%). Three of the thyrotoxicosis patients in heart 
failure clinically, had normal LVEF and FS (50%–75%). This 
is depicted in Figure 1. Thyrotoxicosis patients without heart 
failure who had normal systolic function (31 patients – 62%) 
and enhanced systolic function (11 patients – 22%) are also 
shown in Figure 1. Thyrotoxicosis patients in heart failure had 
significantly lower systolic function than control (Table 2).
Echocardiography showed that the 5 patients who had 
LVEF of ,50% also had dilatation of other chambers of the 
heart. A two-dimensional echogram showing dilated heart 
chambers in thyrotoxicosis is shown in Figure 2.
No echocardiographic findings indicating abnormal sys-
tolic dysfunction were found in the control group.
Electrocardiography showed that two out of the five 
patients with LVEF of ,50% were in atrial fibrillation.
Discussion
This study has shown that congestive heart failure occurs 
in thyrotoxicosis patients in eastern Nigeria. In spite of the 
hyperdynamic state found in thyrotoxicosis, low output heart 
failure with dilated hearts can occur. Is this a true thyrotoxic 
heart muscle disease or secondary to hemodynamic condi-
tions found in thyrotoxicosis?
No definitive answer has been given to this question. 
However studies have demonstrated the presence of fibroblast 
infiltration and degenerative changes as well as TSH-receptor 
(TSH-R) in human heart in Graves’ disease. TSH-R mRNA 
was identified in the human heart using the reverse tran-
scriptase polymerase chain reaction and DNA sequencing.7 
Myocardial damage evidenced by III-labeled monoclonal 
antimyosin antibodies have also occurred in hyperthyroidism 
with heart failure and both myocardial damage, and left ven-
tricular dysfunction disappeared after antithyroid therapy.8
There are hemodynamic conditions in thyrotoxicosis 
that may increase cardiac load and stress and predispose to 
failure. The increased cardiac preload which occurs in thyro-
toxicosis may be due to peripheral vasodilatation, activation 
of the renin–angiotensin–aldosterone system and upregula-
tion of the erythropoietin secretion and red blood cell mass, 
which in turn will increase total blood volume.1
The hospital-based studies by Kolawole et al2 and 
  Danbauchi et al3 showed that 14% and 8% of their patients 
had heart failure, respectively. These figures are lower than 
the 16% in our index study. This may possibly be due to the 
fact that our cohort of patients were pulled from nearby hos-
pitals and late presentation could be largely contributory. It is 
instructive to know that more of the patients in this study had 
Graves’ disease (100%), compared to only 52% of Kolawole 
et al2 patients. Atrial fibrillation, which contributes to heart 
failure in thyrotoxicosis, was found in 4% in Ife2 and 2% in 
the Zaria3 studies respectively. These figures are comparable 
with 4% found in this study.
All the 61 thyrotoxicosis patients studied by Niakara 
et al9 in Burkina Faso had thyrotoxic heart disease, so it 
is not surprising that 80.3% of them had heart failure and 
24.3% had atrial fibrillation. However, only 54.3% of them 
had Graves’ disease.
In the study by Siu et al1 in China, 5.8% of their patients 
had heart failure. In their study there was no significant dif-
ference in the incidence of Graves’ disease between patients 
with and without left ventricular systolic dysfunction.
Table 1 clinical, anthropometric data and thyroid function of 
patients and controls
Parameters  Thyrotoxicosis  
Patients: Mean 
(±SD) 
Control:  
Mean  
(±SD) 
t-test 
value
P- 
value
Age  44 (3.1) 43.5 (5.2) 0.85 .0.05
Weight (kg) 56.0 (5.5) 65 (7.6) 26.4 ,0.05*
Height (meters) 159.5 (6.8) 160.8 (15.9) 1.35 .0.05
Body surface 
area (m2)
1.2 (2.4) 1.6 (0.17) 1.85 ,0.5*
Body mass  
index (kg/m2)
22.04 (6.4) 25.09 (5.4) 21.87 ,0.05*
Pulse (beats/min) 102 (11.9) 78 (5.2) 8.57 ,0.01*
systolic Blood 
Pressure (mmHg)
124.2 (12.5) 122.9 (2.8) 0.12 .0.05
Diastolic Blood 
Pressure(mmHg)
75 (11.4) 79.1 (6.5) 1.5 .0.05
TsH (µu/mL) 0.28 (0.1) 2.3 (1.5) 20.6 ,0.01*
Total T3 (ng/mL) 4.7 (3.9) 1.5 (1.1) 2.5 ,0.01*
Total T4 (ug/mL) 173 (4.2) 56 (2.1) 20.6 ,0.01*
Free T3 (pg/mL) 5.9 (0.9) 2.3 (0.3) 11.9 ,0.01*
Note: *Represents significant value.
Abbreviations: T3, tri-iodothyronine; T4, tetraiodothyronine; TsH, thyroid stimulating 
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Table 2 comparison of proportions of left ventricular systolic dysfunction parameters of thyrotoxicosis patients and control
Parameters Proportions found in  
Thyrotoxicosis Patients PT
Proportions found 
in Control PC 
t-test value P-value
LVeR ,50% 0.10 0.00 2.05 ,0.05*
Fs ,18% 0.12 0.00 2.35 ,0.05*
cardiac index ,2.8 L/min/m2 0.10 0.02 2.52 ,0.05*
cardiac output ,4 L 0.10 0.02 2.1 ,0.05*
Peak aortic systolic velocity ,72 cm/s 0.12 0.00 2.30 ,0.05*
VcF(circumferences/second) ,1.02 0.10 0.00 2.35 ,0.05*
Abbreviations: FS, fractional shortening; VCF, velocity of circumferential fiber shortening; LVEFR, Left ventricular ejection fraction.
50%–75% <50% 50%–75% 75%
-Thyrotoxicosis  +   CCF -
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Figure 1 Bar chart comparing proportions of thyrotoxicosis patients with and without congestive heart failure using left ventricular ejection fraction as a systolic parameter. 
*,50% = systolic dysfunction, 50%–75% = normal systolic function, .75% = enhanced systolic function.Vascular Health and Risk Management
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Dilated hearts, as shown in Figure 2, have been noted 
in other studies to be associated with reduced LVEF.3,9 
Interestingly, restoring normal levels of thyroid hormone 
often reverses the dilation and dysfunction, which makes 
thyrotoxic heart failure a curable disease.
Conclusion
Heart failure can occur in thyrotoxicosis in spite of the 
associated hyperdynamic condition. The underlying mecha-
nism may include direct damage by autoimmune myo-
carditis, congestive circulation secondary to excess sodium 
and fluid retention related to hyperthyroidism or diastolic 
heart failure triggered by sustained tachycardia and or atrial 
fibrillation.10 This study has demonstrated that heart failure 
in thyrotoxicosis may be accompanied with normal or low 
cardiac output state.
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Figure 2 Two-dimensional echocardiogram showing dilated heart chambers.